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to treat the ascending aortic and arch pa-
thology in the standard open surgical fash-
ion and follow the progression of the de-
scending thoracic aorta. As Dobrilovic and
Elefteriades1 expertly point out, expansion
of the descending thoracic aorta after acute
type A dissection may be a slow process.
There may, however, be additional reasons
to consider simultaneous hybrid repair in
this situation.
Total arch replacement involves the use
of deep hypothermic circulatory arrest
(DHCA). The increased risks associated
with this technique have been well docu-
mented, and eliminating DHCA for the
treatment of acute Type A aortic dissec-
tions would potentially make this a safer
and better tolerated procedure. Another al-
ternative hybrid approach would be to re-
pair the entry point tear in the ascending
aorta with standard open surgical tech-
niques (interposition graft or ascending
conduit) and simultaneously bypass the
great vessels with grafts off the newly com-
pleted ascending aortic graft. Simultaneous
deployment of an endoluminal graft in an
antegrade fashion through the ascending
graft, across the aortic arch, and into the
proximal descending thoracic aorta would
accomplish a total arch reconstruction
without the need for DHCA.3 This ap-
proach maximizes the advantages of
endovascular technologies by making a
complex procedure less invasive while sta-
bilizing the true lumen of the descending
thoracic aorta. We have shown that stabi-
lizing the true lumen in the descending
thoracic aorta is an active process that in
time leads to progressive expansion of the
true lumen and continued thrombosis of the
false lumen.4 In addition to potentially pre-
venting future complications and need for
reoperation, stabilization of the true lumen
and continued active true lumen expansion
after thoracic endografting can potentially
improve distal organ perfusion.
Hybrid approaches to complex aortic
pathologies may allow us to offer surgical
repair to patients with acute type A aortic
dissection who might not otherwise tolerate
DHCA. The less invasive advantages of
simultaneous arch exclusion with an endolu-
minal graft after great vessel transposition
could accelerate patient recovery and provide
the added potential advantage of distal true
lumen stabilization. I therefore believe that the
surgical paradigm may be shifting toward
hybrid approaches, not away from them.
Grayson H. Wheatley III, MD
Arizona Heart Institute
Phoenix, Ariz
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Reply to the Editor:
We appreciate the thoughtful commentary
from Dr Wheatley. We are aware of the
imaginative work being done in catheter-
based treatment of aortic diseases at the
Arizona Heart Institute.
There are certainly many clever ways to
“manipulate” the anatomy of the aortic
arch to make stent therapy feasible, and we
applaud the exploration of these tech-
niques. We disagree, however, with the
undercurrent of fear of deep hypothermic
circulatory arrest (DHCA) manifest in Dr
Wheatley’s letter.
DHCA is a proven modality in aortic sur-
gery, with a vast clinical experience demon-
strating its clinical utility and safety.1-4 At
our own institution, Dr Arjet Gega has just
completed (for upcoming submission) a re-
view of 400 patients operated on under
“straight” DHCA, without any adjunctive
retrograde or antegrade cerebral perfusion.
This experience included all comers: as-
cending, arch, descending, and thoracoab-
dominal; elective and emergency; and rup-
tured and nonruptured. Overall mortality
was 6.5%, stroke rate was 4.9%, and reex-
ploration for bleeding was 3.9%. Cerebral
protection was excellent, with most strokes
embolic in origin. The supposed bleeding
diathesis of DHCA is simply not a prob-
lem. It is not uncommon for us to find the
morning’s DHCA patient extubated, vi-
brantly conversant, and having a light sup-
per by the time of evening rounds. DHCA
need not be feared. At our institution we
marvel at the protective abilities of this
technique, and we are pleased to call upon
them at every opportunity.
Current results for surgery under DHCA
at many expert centers worldwide sets a
standard that will be hard to exceed with
clever extra-anatomic and catheter based
modalities. In fact, it remains to be shown
in careful analysis of large clinical series
that the alternative modalities can even come
close to meeting the excellent results of tra-
ditional, direct arch surgery under DHCA.
John A. Elefteriades, MD
Nikola Dobrilovic, MD
Arjet Gega, MD
Department of Cardiothoracic Surgery
Yale University School of Medicine
New Haven, Conn
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When less is more: Go slowly when
repopulating a decellularized valve
in vivo!
To the Editor:
We read with interest the recent article by
Juthier and colleagues1 describing the ef-
fects of granulocyte colony-stimulating
factor (GCSF) on decellularized xenogenic
heart valves implanted in systemic circula-
tion in sheep. The hypothesis was tested
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that bone marrow cell mobilization by
GCSF would facilitate in vivo repopulation
with endothelial and smooth muscle pro-
genitor cells; however, it was found that
the valves actually deteriorated sooner than
the same scaffolds in untreated animals.
Juthier and colleagues1 concluded quite ap-
propriately that GCSF accelerated valve
deterioration through increased inflamma-
tory reaction, and they suggested searching
for alternative strategies to improve scaf-
fold recolonization. Our group has been
tackling this very problem in the past, and
we believe we have found a promising so-
lution. In 2004, we reported on the biologic
and mechanical properties of biomatrix/
polymer composite material for heart valve
tissue engineering.2 In essence, porcine
aortic valves were enzymatically decellu-
larized and coated or penetrated with a
slowly biodegradable polymer with known
favorable biocompatibility and hemocom-
patibility. By doing so, we produced valve
scaffold tissue that induces less coagulation
and complement activation in vitro, dis-
played favorable behavior in a rabbit aorta
in vivo model, and, most importantly, gave
superior results in terms of endothelializa-
tion and clot deposition on implantation in
both pulmonary and aortic positions in
sheep. Moreover, polymer impregnation
can also help improve the mechanical prop-
erties of the valve leaflet, which may be
particularly important when enzymatic pro-
cesses are used for decellularization.3 The
polymer impregnation process does not in-
volve glutaraldehyde- or formaldehyde-
based fixation steps, so both the biologic
and structural properties of the extracellu-
lar matrix (ECM) components are left in-
tact, and repopulation with host cells is not
hampered (Figure 1). It also masks platelet-
activating moieties on ECM components,
thereby reducing the risk of collagen-
induced platelet aggregation during the
early postimplantation phase.
Juthier and colleagues1 convincingly
showed that removal of all xenogenic cells
without altering the biologic characteristics
of the ECM components reduces the in-
flammatory response in sheep and im-
proves in vivo repopulation with host cells.
However, as they themselves pointed out,
some immunogenicity of xenogenic ECM
inevitably persists.4-6 Even the smallest
amount of residual cell detritus can trigger
cellular immune response, with macro-
phage invasion and subsequent blood ves-
sel ingrowth, and the various ECM compo-
nents possess an inherent immunogenic
potential when exposed in a xenogenic set-
ting. We were therefore not surprised to
read that massive inflammatory stimulation
by GCSF accelerated inflammatory valve
matrix infiltration and structural deteriora-
tion. After all, the mobilization of (theoret-
ically) beneficial bone marrow stem cells
and endothelial progenitor cells by GCSF
is secondary to the release of mature leu-
kocytes, and Juthier and colleagues1 ele-
gantly demonstrated the substantial in-
crease in white blood cell count even in the
sheep model. Taken together, we believe
that any proinflammatory action should be
avoided soon after in vivo implantation of
decellularized ECM conduits. The rapid
failure of Synergrafts in children (with
their pronounced inflammatory response to
extracorporeal circulation) adds to the evi-
dence.7 On the contrary, measures that help
reduce the susceptibility of decellularized
ECM conduits to cellular and humoral in-
flammatory are needed. Coating with bio-
degradable polymer is one such approach,
masking proinflammatory components dur-
ing the early postimplantation phase and
thus buying time for vascular host cell re-
Figure 1. A, Decellularized porcine heart valve impregnated with biodegradable poly-
(hydroxy)butyrate to reduce xenoreactivity and improve hemocompatibility and mechan-
ical performance for a limited time. B, Note that polymer impregnation process preserves
porosity of decellularized ECM scaffold, so that repopulation with host cells is not
disturbed.
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population with re-endothelialization and
matrix turnover.
Christof Stamm, MDa
Gustav Steinhoff, MDb
Dept. of Cardiothoracic and Vascular Surgery
Deutsches Herzzentrum Berlin
Berlin, Germanya
Dept. of Cardiac Surgery
Universität Rostock
Rostock, Germanyb
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Reply to the Editor:
We thank Drs Stamm and Steinhoff for
their comments. In the field of tissue-
engineered heart valves, the choice between
synthetic and biologic (either allogeneic or
xenogenic) scaffolds is a major concern. As
have many others, we hypothesized that the
best valve replacement remains a heart
valve. Porcine heart valves have been used
for decades in cardiac surgery with good
clinical results, especially in terms of du-
rability in elderly patients. In particular,
hemodynamic behavior of the latest gener-
ation of porcine bioprostheses, the stentless
porcine valves, was found to be similar to
that of native aortic valves.
These scaffolds, however, need preim-
plantation treatment to avoid acute xeno-
genic rejection. Decellularization seems a
promising choice, because it both induces a
decrease of cell-induced acute rejection
and may allow autologous cell recoloniza-
tion. Our study suggests that nonenzymatic
decellularization may be used without in-
ducing mechanical failure of the matrix in
vivo. Previous decellularization procedures,
such as deep osmotic shock (with distilled
water)1 or use of trypsin and ribonuclease,2
have resulted in graft failure.3 Adverse im-
mune reaction was advocated; however, we
observed that a less aggressive decellulariza-
tion procedure did not induce mechanical
failure after 4-month exposure in the sys-
temic arterial strain, suggesting that the de-
cellularization procedure was critical for the
in vivo outcome.
Stamm and coworkers4 used an enzy-
matic decellularization procedure, but they
reinforced the scaffold with a biodegrad-
able polymer coating. Short-terms results
were satisfactory, but little is known about
the long-term behavior of these polymers.
Previous long-term studies on biodegrad-
able scaffolds as heart valve substitutes
have reported fibrosis, retraction, and graft
dysfunction.5
As noted by Stamm and Steinhoff, co-
agulation and complement activation, with
the risk of collagen-induced platelet aggre-
gation early after implantation, are a major
concern with decellularized matrices. We
found no evidence of thrombus formation
on implanted decellularized scaffolds, and
thrombosis occurred only in a nondecellu-
larized xenograft. However, it should be
underlined that in our study all animals
received aspirin therapy (500 mg daily), as
in usual clinical practice with biologic
valves.
Finally, our study suggests that xenogenic
scaffolds decellularized through a nonenzy-
matic procedure do not induce matrix failure
in a sheep model, and interestingly allow
partial recellularization in vivo. Longer im-
plantation studies are mandatory to confirm
these mechanical results. Moreover, because
autologous cell recolonization of these decel-
lularized scaffolds remains only partial, other
strategies to induce complete recolonization
by proper autologous cells are needed.
André Vincentelli, MD, PhD
Francis Juthier, MD
Brigitte Jude, MD, PhD
Institut National de la Santé et de la
Recherche Medicale (Inserm) ERI-9,
Faculté de Médecine
and
Clinique de Chirurgie Cardio-vasculaire
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Lung transplantation in a patient
with Mounier-Kuhn syndrome
To the Editor:
We previously reported the first case of
successful lung transplantation in a patient
with Mounier-Kuhn syndrome.1 The pa-
tient was a 59-year-old woman with a his-
tory of bronchiectasis of unknown etiology
since childhood. The patient developed
very severe obstructive lung disease and
multiple episodes of pneumonia due to
Pseudomonas aeruginosa that necessitated
hospitalization. Computed chest tomogra-
phy and bronchoscopy were diagnostic of
Mounier-Kuhn syndrome. The patient un-
derwent bilateral lung transplantation, and
the degree of bronchomegaly was not as
pronounced as the tracheomegaly and posed
little difficulty during transplantation. The
patient had a difficult postoperative course,
with multiple failed extubations, P aerugi-
nosa pneumonia, and prolonged respiratory
failure necessitating tracheostomy. The pa-
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